ALMS

Alumis Inc. Common Stock

$6.06

Current Price

All

AI analysis

Read what the AI thinks of Alumis Inc. Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$3.81

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$0.76

Nov 12

Posts

No posts about ALMS yet.

About Alumis Inc. Common Stock

Alumis is a drug developer that has no approved product on the market yet. It works on pills for autoimmune diseases, where the immune system attacks the body's own tissue, with conditions like psoriasis and lupus as targets. Revenue is close to zero, so the company pays for its research by selling shares and raising money from investors.